Biyolojik Ajan Tedavisi Alan Ağır Astımlı Hastalarda COVID-19 Pandemisi Sırasında Tedaviye Uyumdaki Değişiklikler

Yıl 2022, Cilt: 12 Sayı: 5, 678 - 684, 30.09.2022

Hale Ateş , İlkay Koca Kalkan , Kurtuluş Aksu , Musa Topel , Selma Yeşilkaya , Şenay Demir , Sakine Nazik Bahçecioğlu

https://doi.org/10.16899/jcm.1168725

Öz

Amaç: Bu çalışmada, kliniğimizde omalizumab ve mepolizumab tedavisi alan ağır astımlı hastalarda COVID-19 pandemisinin tedaviye uyum üzerindeki etkilerinin değerlendirilmesi amaçlanmıştır.
Gereç ve Yöntem: Çalışmaya 45'i omalizumab ve 8'i mepolizumab kullanan ağır astımlı 53 hasta dahil edildi. Hastaların tıbbi kayıtları isimsiz ve geriye dönük olarak kaydedildi.
Bulgular: Çalışma popülasyonunda omalizumab kullanan hasta oranının pandemi öncesi 1 yıllık döneme göre pandemi döneminde azaldığı görüldü. Omalizumab kullanan hastaların yaklaşık %51'inin rutin tedavi dozlarını kaçırdığı gözlendi. Tedavi dozlarının atlanmasındaki en büyük faktör, hastaneye kabul edildikten sonra COVID-19'a yakalanma korkusuydu. Mepolizumab grubunda pandemi döneminde biyolojik ajan kullanma oranı pandemi öncesi 1 yıl öncesine göre artış gösterdi. Bu gruptaki hastaların %37,5'inde doz atlama gözlemlendi ve doz atlamanın en büyük risk faktörünün hastaneye başvuruda COVID-19 kapma korkusu olduğu bulundu.
Sonuç: Bu çalışmada, bir sağlık kuruluşunda sağlık profesyoneli gözetiminde uygulanan biyolojik ajan tedavilerinin pandemi döneminde ağır astımı olan hastalarda kullanım süre ve oranlarında azalma olduğu saptanmıştır.

Anahtar Kelimeler

Koronavirus Anksiyete Ölçeği, Mepolizumab, Omalizumab, SARS-CoV-2

Changes in Treatment Adherence During the COVID-19 Pandemic in Patients with Severe Asthma Receiving Biologic Agent Treatment

Öz

Aim: This study aimed to evaluate the effects of the COVID-19 pandemic on treatment adherence in patients with severe asthma who were receiving omalizumab and mepolizumab treatment in our clinic.
Material and Method: A total of 53 patients with severe asthma, 45 of whom were using omalizumab and 8 of whom were using mepolizumab, were included in the study. The medical records of the patients were recorded anonymously and retrospectively.
Results: It was seen that the rate of patients using omalizumab in the study population decreased during the pandemic period compared to the 1-year period before the pandemic. It was observed that approximately 51% of the patients using omalizumab missed routine treatment doses. The major factor in skipping treatment doses was the fear of contracting COVID-19 upon admission to the hospital. In the mepolizumab group, the rate of using biologic agents during the pandemic period increased compared to 1 year before the pandemic. Dose skipping was observed among 37.5% of the patients in this group and it was found that the major risk factor for skipping a dose was the fear of contracting COVID-19 upon admission to the hospital.
Conclusion: In this study, it was found that there was a decrease in the duration and rate of use of biologic agent therapies administered in a health institution under the supervision of a healthcare professional among patients with severe asthma during the pandemic.

Anahtar Kelimeler

Coronavirus Anxiety Scale, Mepolizumab, Omalizumab, SARS-CoV-2

Kaynakça

• Kaplan A, van Boven JF, Ryan D, Tsiligianni I, Bosnic-Anticevich S, Group RAW. GINA 2020: Potential Impacts, Opportunities, and Challenges for Primary Care. J Allergy Clin Immunol Pract 2021;9(4):1516-9.
• Krings JG, McGregor MC, Bacharier LB, Castro M. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent. J Allergy Clin Immunol Pract 2019;7(5):1379-92.
• Cote A, Godbout K, Boulet LP, The management of severe asthma in 2020. Biochem Pharmacol 2020;179:114112.
• Schoettler N, Strek ME, Recent Advances in Severe Asthma: From Phenotypes to Personalized Medicine. Chest 2020;157(3):516-28.
• Papadopoulos NG, Barnes P, Canonica GW, et al., The evolving algorithm of biological selection in severe asthma. Allergy 2020;75(7):1555-63.
• Zhu N, Zhang D, Wang W, et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382(8):727-33.
• Kaye L, Theye B, Smeenk I, Gondalia R, Barrett MA, Stempel DA. Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic. J Allergy Clin Immunol Pract 2020;8(7):2384.
• Akenroye AT, Wood R, Keet C. Asthma, biologics, corticosteroids, and coronavirus disease 2019. Ann Allergy Asthma Immunol 2020;125(1):12.
• Reddel HK, Bacharier LB, Bateman ED, et al., Global Initiative for Asthma (GINA) Strategy 2021–Executive summary and rationale for key changes. J Allergy Clin Immunol Pract 2021.
• Beasley R, Braithwaite I, Semprini A, et al., ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma 2020, Eur Respiratory Soc.
• Lee SA, Coronavirus Anxiety Scale: A brief mental health screener for COVID-19 related anxiety. Death studies 2020;44(7):393-401.
• Bicer İ, Çakmak C, Demir H, Kurt ME. Koronavirüs anksiyete ölçeği kısa formu: Türkçe geçerlik ve güvenirlik çalışması. Anadolu Klinigi 2020;25(Special Issue on COVID 19):216-25.
• Girija A, Shankar EM, Larsson M. Could SARS-CoV-2-induced hyperinflammation magnify the severity of coronavirus disease (COVID-19) leading to acute respiratory distress syndrome? Front immunol 2020;11:1206.
• Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020;87(4):281-6.
• Maveddat A, Mallah H, Rao S, Ali K, Sherali S, and Nugent K, Severe acute respiratory distress syndrome secondary to coronavirus 2 (SARS-CoV-2). Int J Occup Environ Med 2020;11(4):157.
• Liu S, Cao Y, Du T, Zhi Y. Prevalence of comorbid asthma and related outcomes in COVID-19:a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2021;9(2):693-701.
• Choi YJ, Park J-Y, Lee HS, et al., Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J 2021;57(3).
• Kwok WC, Tam AR, Ho JCM, et al., Asthma, from mild to severe, is an independent prognostic factor for mild to severe Coronavirus disease 2019 (COVID‐19). Clin Respir J 2022.
• Goyal M, Singh P, Singh K, Shekhar S, Agrawal N, Misra S. The effect of the COVID‐19 pandemic on maternal health due to delay in seeking health care:experience from a tertiary center. Int J Gynaecol Obstet 2021;152(2):231-5.